2023年4月20日

Ariceum療法——一個私營生物技術公司開發放射性藥物產品某些不易治愈癌症的診斷和治療,宣布成功完成一係列擴展融資,進一步提高€2275萬€2500萬係列融資後宣布2022年6月。一輪融資是由新投資者共同Andera夥伴和晨鳥與參與風險投資從現有投資者Pureos Bioventures,現在翻倍原來的投資公司。作為資金的一部分,奧利維爾·Litzka Andera Partners的合夥人和Christoph Massner晨鳥,負責人將加入Ariceum董事會。Ariceum計劃用所得資金進一步推進其臨床管道和建立公司專注於其資產和專有肽衍生物,Satoreotide,以及建立進一步的管道項目。Satoreotide放射性藥物的藥物和生長激素抑製素的拮抗劑2型(SST2)受體在許多癌症中,其中包括某些神經內分泌和其他激進,不易治愈的癌症預後較差,如小細胞肺癌(SCLC)。和Ariceum計劃使用satoreotide theranostic”的診斷和治療腫瘤表達SST2受體。Satoreotide在早期臨床開發和今天已為超過100名患者包括超過150治療政府在不同的適應症。關鍵引用:“隨著我們繼續在Ariceum取得承諾的進步,新基金將使我們能夠推進我們臨床的診斷、監測和精確治療改善那些麵臨的生活非常具有挑戰性的癌症。額外的投資是強烈支持我們的靶向放射治療產品,反映了放射性藥物提供機會在可視化和治療癌症。我們很高興歡迎Andera夥伴和晨鳥風險資本投資集團,要感謝我們現有投資者的繼續支持。” – Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics “At Andera we have been following the radiopharmaceuticals space for some time, looking for an opportunity to support a compelling project. As a result, we are now very happy to be able to back the talented and experienced team of Ariceum with a first clinical project centered around a meaningful disease application in Small Cell Lung Cancer. It is great to support the company in its bold ambition to build a pipeline of radiopharma projects through deals and partnerships. We are also joining an already powerful board of experts and strong European VCs. Altogether, we believe these are solid grounds to build a leading biotech company in the radiopharmaceuticals field.” – Olivier Litzka, PhD, Partner of Andera Partners “We are delighted to support Ariceum as it advances its proprietary clinical programs to address aggressive cancers with a poor prognosis. Earlybird is especially excited about Ariceum’s ability to stratify patients for treatment via its theranostics approach. This will provide the best possible patient outcomes and attractive health economics. I look forward to working with Ariceum’s experienced management team and strong investor base as it enters its next development stage.” – Christoph Massner, PhD, Principal of Earlybird Venture Capital Trending on Pulse 2.0